Navigation Links
Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents

WALTHAM, Mass., Aug. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade. Through 2013, the market will decrease by 1.4 percent annually and thereafter the annual decline will slow to 1 percent through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Hypertension finds that the major contributor to market decline will be the increasing generic availability of antihypertensive agents. By 2018, Diovan alone will lose more than $1 billion in sales, owing to generic erosion of the agent which will begin in 2010 in the U.S., in 2011 in Europe and in 2013 in Japan. Additionally, agents from drug classes that are typically used in first-, second-, and third-line therapy -- such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), calcium-channel blockers (CCBs), and diuretics -- will all be subject to generic competition.

The report also finds that near-term opportunity in the hypertension market -- which is saturated with effective, well-established treatments -- lies in the development of therapies that offer greater convenience. Fixed-dose combinations such as CCB/renin-angiotensin-aldosterone system (RAAS) inhibitors and CCB/RAAS/diuretics will capitalize on this opportunity. By 2012, three fixed-dose combinations -- Novartis's Exforge HCT, Daiichi Sankyo's olmesartan/amlodipine/HCT, and Novartis's aliskiren/amlodipine/HCT -- will each be available in the world's major markets. While these agents will offer considerable improvements in convenience over currently available fixed-dose combinations, interviewed experts express differing views on their likely uptake.

"Some experts welcome the greater convenience of these combination therapies which could help reduce patients' pill burden," said Decision Resources Analyst Caroline Gates. "However, others indicate that they prefer to use single agents in order to titrate individual doses on a patient-by-patient basis, especially in cases of advanced hypertension where at least three antihypertensive agents are typically required to control blood pressure."

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources                Decision Resources, Inc.
    Christopher Comfort               Elizabeth Marshall
    781-296-2597                      781-296-2563 

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
2. Presentation of Phase IIa Results for Cytos Biotechnologys Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
3. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
4. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
5. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
6. Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
7. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
8. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
9. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
10. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
11. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider ... , today announced that the company has set a new ... 391% quarter on quarter growth posted for Q3 of 2014 to ... and Mexico , with the establishment of an ... 2015. --> United Kingdom and ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):